Overview
Sound Pharmaceuticals (SPI) is a privately held biopharmaceutical company in Seattle, WA.
Sound Pharmaceuticals, Inc. (SPI) is developing therapeutics that will enable doctors and patients to prevent and treat various forms of hearing loss. Sensorineural hearing loss is the third largest disease in the industrialized world and affects 50 million Americans. Estimates from the NIH and the CDC place the total annual costs of hearing loss at approximately $50 billion per year in the U.S. alone.
LEARN MORE
Recent News
Jul 14
SEATTLE–(BUSINESS WIRE)–Sound Pharmaceuticals is pleased to announce that it completed enrollment of its second Phase 3 open label study of SPI-1005 for the Treatment of Meniere’s Disease (MD). Read More
Dec 01
SEATTLE–(BUSINESS WIRE)–Sound Pharmaceuticals (SPI) is pleased to announce that the FDA has granted its investigational new drug, SPI-1005, Breakthrough Therapy Designation (BTD) for the treatment of hearing loss in patients with Meniere’s disease (MD). Read More
Jul 08
SEATTLE — Sound Pharmaceuticals is pleased to announce that it has been invited to present its R&D and financing goals at two upcoming industry conferences this month. Read More
Oral treatments for acute and chronic hearing loss
LEARN MORE
Oral combination for the treatment of acute ototoxicity
LEARN MORE
Locally delivered treatments for hearing restoration
LEARN MORE